Quick Answer
Forte Biosciences, Inc. reported Operating Income Loss of -$70.66 million for the year ending 2025.
- Forte Biosciences, Inc. showed a decrease of -93.0% in Operating Income Loss from 2024 to 2025.
- This data is from Forte Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), Forte Biosciences, Inc.'s Operating Income Loss has declined by 207.8%.
- Historical annual values: Fiscal year 2025: -$70.66 million | Fiscal year 2024: -$36.60 million | Fiscal year 2023: -$32.49 million | Fiscal year 2022: -$13.90 million | Fiscal year 2021: -$21.49 million | Fiscal year 2020: -$46.28 million | Fiscal year 2019: -$4.06 million | Fiscal year 2018: -$45.85 million | Fiscal year 2017: -$37.63 million | Fiscal year 2016: -$31.69 million | Fiscal year 2015: -$22.95 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: